Bevacizumab Biosimilars Market Report 2026

Bevacizumab Biosimilars Market Overview

• Bevacizumab Biosimilars market size has reached to $1.64 billion in 2025 • Expected to grow to $2.42 billion in 2030 at a compound annual growth rate (CAGR) of 8.2% • Growth Driver: Growing Cancer Prevalence Fuels Bevacizumab Biosimilars Market Expansion • Market Trend: Advancements In Indication-Expanded Biologic Formulations Enhancing Treatment Accessibility And Patient Compliance • North America was the largest region in 2025.

What Is Covered Under Bevacizumab Biosimilars Market?

Bevacizumab biosimilars are a type of medication that is highly similar to a reference biologic drug called bevacizumab. It is commonly used to inhibit the growth of new blood vessels in tumors, thereby slowing down their progression. The main types of bevacizumab biosimilar products are avastin, mvasi, zirabev, aybintio, and others. Avastin is the brand name for the original biological drug bevacizumab, referring to an anti-angiogenic therapy that inhibits the formation of new blood vessels. They are available in various distribution channels, such as hospital pharmacies, online pharmacies, retail pharmacies, and others. They are used for various applications such as colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, and ovarian cancer.

What Is The Bevacizumab Biosimilars Market Growth Forecast?

The bevacizumab biosimilars market size is expected to see strong growth in the next few years. It will grow to $2.42 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to increasing biosimilar approvals, expansion in emerging markets, integration of AI in drug development, growing preference for outpatient oncology care, strategic collaborations among pharma companies. Major trends in the forecast period include increased adoption of biosimilars in oncology, cost-effective treatment alternatives, rising regulatory approvals for biosimilars, expansion of hospital and retail pharmacy networks, growth of specialty cancer treatment centers.

Global Bevacizumab Biosimilars Market Segmentation

1) By Product: Avastin, Mvasi, Zirabev, Aybintio, Other Products 2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels 3) By Application: Colorectal Cancer, Non-small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer

What Is The Driver Of The Bevacizumab Biosimilars Market?

The rising prevalence of cancer cases is expected to propel the growth of the bevacizumab biosimilar market going forward. Cancer incidence refers to the number of new cancer cases in a specific population for a given period. Bevacizumab is a biologic that inhibits tumor angiogenesis, which can lead to tumor shrinkage and growth inhibition, and it is comparable to reference biologics in terms of efficacy and safety in treating patients with advanced non-small cell lung cancer or metastatic colorectal cancer. For instance, in October 2025, according to the NHS England, a UK-based government department, there were 354,820 new cancer diagnoses in England in 2023, which is 8,605 more than in 2022. Therefore, the rising prevalence of cancer cases drives the bevacizumab biosimilars industry.

Key Players In The Global Bevacizumab Biosimilars Market

Major companies operating in the bevacizumab biosimilars market are Cipla Limited, Reliance lifesciences Pvt. Ltd., Fujifilm Kyowa Kirin Biologics Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan Inc., Daiichi Sankyo Company Limited, Beaconpharma Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Shanghai Henlius Biotech Inc., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Biocon Ltd., Intas Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Samsung Bioepis Co. Ltd., Celltrion Inc., Coherus BioSciences Inc., Hetero Drugs Ltd., Apotex Inc., BioXpress Therapeutics SA, mAbxience SA

Global Bevacizumab Biosimilars Market Trends and Insights

Major companies operating in the bevacizumab biosimilars market are focusing on technological advancements, such as next‑generation indication‑expanded formulations, to meet the rising demand for more versatile and affordable biologic therapies across oncology and non-oncology indications. These advanced formulations adapt the core bevacizumab antibody to new routes or indications enabling non‑oncologic use (e.g., ophthalmology) or more patient-compliant dosing while retaining the same VEGF‑neutralizing mechanism that traditional intravenous bevacizumab uses. For instance, in March 2024, Dr. Reddy’s Laboratories, an India‑based pharmaceutical company, launched Versavo (bevacizumab) in the UK a high‑quality biosimilar of Avastin (bevacizumab) produced for oncology applications, bringing the cost of metastatic colorectal cancer, lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, ovarian cancer, and breast cancer treatments within reach for more patients. Versavo is supplied in 100 mg and 400 mg single‑use vials, matching standard bevacizumab dosing while offering a biosimilar cost-benefit that helps reduce the financial burden on healthcare systems and patients relying on anti‑VEGF therapy.

What Are Latest Mergers And Acquisitions In The Bevacizumab Biosimilars Market?

In February 2024, Biocon Biologics Ltd, an India-based provider of fully integrated biosimilar development, manufacturing, and commercialization services, partnered with Sandoz Australia to strengthen its global commercial footprint by leveraging Sandoz’s established marketing and distribution network to expand access to its oncology biosimilars such as Trastuzumab and Bevacizumab across Australia. Sandoz Australia is an Australia-based provider of high-quality generics and biosimilars.

Regional Insights

North America was the largest region in the bevacizumab biosimilars market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Bevacizumab Biosimilars Market?

The bevacizumab biosimilars market consists of sales of byvasda, cizumab, alymsys, bevax, and cyramza. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Bevacizumab Biosimilars Market Report 2026?

The bevacizumab biosimilars market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the bevacizumab biosimilars industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.